Tobin Schilke

Insider Reports History

Location
South San Francisco, CA
Signature
Tobin Schilke
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Tobin Schilke:

Company Role Class Num Shares Value Price $ Report Date Ownership
Crinetics Pharmaceuticals, Inc. Chief Financial Officer Common Stock 52,000 $2,031,640 $39.07 10 Mar 2025 Direct
Revance Therapeutics, Inc. CFO Common Stock 0 $0 $3.65 06 Feb 2025 Direct
Crinetics Pharmaceuticals, Inc. Chief Financial Officer Stock Option (Right to Buy) 80,000 10 Mar 2025 Direct

Insider Reports Filed by Tobin Schilke

Symbol Company Period Transactions Value $ Form Type Role Filing Time
CRNX Crinetics Pharmaceuticals, Inc. 10 Mar 2025 2 $0 4 Chief Financial Officer 11 Mar 2025, 16:30
CRNX Crinetics Pharmaceuticals, Inc. 28 Feb 2025 0 $0 3 Chief Financial Officer 05 Mar 2025, 16:30
/report/000095017025015362-schilke-tobin-2025-02-04 Revance Therapeutics, Inc. 04 Feb 2025 4 -$357,696 4 CFO 06 Feb 2025, 15:59
/report/000095017025014824-schilke-tobin-2025-02-03 Revance Therapeutics, Inc. 03 Feb 2025 1 $0 4 CFO 05 Feb 2025, 19:53
/report/000147929025000005-schilke-tobin-2024-12-31 Revance Therapeutics, Inc. 31 Dec 2024 1 +$2,184 4 CFO 03 Jan 2025, 16:34
/report/000147929024000103-schilke-tobin-2024-06-30 Revance Therapeutics, Inc. 30 Jun 2024 1 +$2,184 4 CFO 02 Jul 2024, 17:47
/report/000147929024000066-schilke-tobin-2024-03-15 Revance Therapeutics, Inc. 15 Mar 2024 2 -$67,479 4 CFO 19 Mar 2024, 18:44
/report/000147929024000051-schilke-tobin-2024-02-29 Revance Therapeutics, Inc. 29 Feb 2024 1 $0 4 CFO 04 Mar 2024, 16:44
/report/000147929024000015-schilke-tobin-2024-01-31 Revance Therapeutics, Inc. 31 Jan 2024 2 $0 4 CFO 02 Feb 2024, 16:46
/report/000147929024000005-schilke-tobin-2023-12-31 Revance Therapeutics, Inc. 31 Dec 2023 1 +$3,242 4 CFO 03 Jan 2024, 16:48
/report/000147929023000099-schilke-tobin-2023-08-11 Revance Therapeutics, Inc. 11 Aug 2023 2 -$212,076 4 CFO 15 Aug 2023, 16:16
/report/000147929023000083-schilke-tobin-2023-06-30 Revance Therapeutics, Inc. 30 Jun 2023 2 -$30,592 4 CFO 05 Jul 2023, 21:11
/report/000147929023000077-schilke-tobin-2023-06-01 Revance Therapeutics, Inc. 01 Jun 2023 2 -$98,070 4 CFO 05 Jun 2023, 18:06
/report/000147929023000056-schilke-tobin-2023-05-01 Revance Therapeutics, Inc. 01 May 2023 1 -$101,472 4 CFO 02 May 2023, 16:01
/report/000147929023000053-schilke-tobin-2023-04-03 Revance Therapeutics, Inc. 03 Apr 2023 1 -$102,912 4 CFO 04 Apr 2023, 16:24
/report/000147929023000041-schilke-tobin-2023-03-15 Revance Therapeutics, Inc. 15 Mar 2023 1 -$114,600 4 CFO 17 Mar 2023, 15:21
/report/000147929023000031-schilke-tobin-2023-03-01 Revance Therapeutics, Inc. 01 Mar 2023 1 -$107,234 4 CFO 02 Mar 2023, 20:25
/report/000147929023000018-schilke-tobin-2023-02-15 Revance Therapeutics, Inc. 15 Feb 2023 1 -$69,243 4 CFO 16 Feb 2023, 19:28
/report/000147929023000015-schilke-tobin-2023-01-31 Revance Therapeutics, Inc. 31 Jan 2023 2 -$110,755 4 CFO 02 Feb 2023, 20:38
/report/000147929023000012-schilke-tobin-2023-01-20 Revance Therapeutics, Inc. 20 Jan 2023 1 -$31,000 4 CFO 23 Jan 2023, 16:35
/report/000147929023000007-schilke-tobin-2023-01-09 Revance Therapeutics, Inc. 09 Jan 2023 3 -$100,525 4 CFO 10 Jan 2023, 19:06
/report/000147929023000003-schilke-tobin-2022-12-31 Revance Therapeutics, Inc. 31 Dec 2022 1 +$7,856 4 CFO 03 Jan 2023, 15:29
/report/000147929022000106-schilke-tobin-2022-12-15 Revance Therapeutics, Inc. 15 Dec 2022 1 -$33,476 4 CFO 16 Dec 2022, 15:12
/report/000147929023000036-schilke-tobin-2022-09-22 Revance Therapeutics, Inc. 22 Sep 2022 2 -$584,884 4 CFO 09 Mar 2023, 20:46
/report/000147929022000072-schilke-tobin-2022-06-30 Revance Therapeutics, Inc. 30 Jun 2022 1 +$11,336 4 CFO 05 Jul 2022, 18:15
/report/000120919122019713-schilke-tobin-2022-03-15 Revance Therapeutics, Inc. 15 Mar 2022 1 -$41,165 4 Chief Financial Officer 17 Mar 2022, 17:48
/report/000147929022000021-schilke-tobin-2022-02-15 Revance Therapeutics, Inc. 15 Feb 2022 2 -$39,035 4 CFO 17 Feb 2022, 19:49
/report/000147929023000075-schilke-tobin-2022-02-02 Revance Therapeutics, Inc. 02 Feb 2022 2 -$739,338 4 CFO 16 May 2023, 20:29
/report/000147929022000014-schilke-tobin-2022-02-02 Revance Therapeutics, Inc. 02 Feb 2022 1 $0 4 CFO 04 Feb 2022, 19:31
/report/000147929022000002-schilke-tobin-2021-12-31 Revance Therapeutics, Inc. 31 Dec 2021 1 +$5,604 4 CFO 04 Jan 2022, 19:58
/report/000147929021000177-schilke-tobin-2021-12-15 Revance Therapeutics, Inc. 15 Dec 2021 1 -$24,772 4 CFO 17 Dec 2021, 16:31
/report/000147929021000132-schilke-tobin-2021-06-30 Revance Therapeutics, Inc. 30 Jun 2021 1 +$10,744 4 CFO 02 Jul 2021, 19:53